Effect of drug reminder packaging on medication adherence: a systematic review revealing research gaps by unknown
Boeni et al. Systematic Reviews 2014, 3:29
http://www.systematicreviewsjournal.com/content/3/1/29RESEARCH Open AccessEffect of drug reminder packaging on medication
adherence: a systematic review revealing research
gaps
Fabienne Boeni1*, Esther Spinatsch1, Katja Suter2, Kurt E Hersberger1 and Isabelle Arnet1Abstract
Background: This was a systematic review of the literature in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statement. Evidence mapping was used to reveal the effect of
drug reminder packaging on medication adherence, to identify research gaps and to make suggestions for future
research.
Methods: PubMed, Embase, CINAHL and PsycINFO were searched with an end date of September 2013 using
the Medical Subject Headings (MeSH) term ‘medication adherence’ and 20 different search terms for ‘drug reminder
packaging’, limited to the English and German languages. Additional references were identified through cross-referencing.
All prospective controlled trials with an intervention using drug reminder packaging for patients taking at least one
medication without the assistance of a health-care professional were included in the evidence mapping of the
effect of drug reminder packaging on adherence and outcomes according to the Economic, Clinical and
Humanistic Outcomes (ECHO) model.
Results: A total of 30 studies met the inclusion criteria: 10 randomized controlled trials, 19 controlled clinical
trials and 1 cohort study. Drug reminder packaging had a significant effect on at least one adherence parameter
in 17 studies (57%). The methodological quality was strong in five studies. Two studies provided complete
information. Clear research gaps emerged.
Conclusions: Overall, the studies showed a positive effect of drug reminder packaging on adherence and
clinical outcomes. However, poor reporting and important gaps like missing humanistic and economic
outcomes and neglected safety issues limit the drawing of firm conclusions. Suggestions are made for future
research.
Keywords: medication adherence, patient compliance, polypharmacy, drug reminder packaging,
multicompartment adherence aid, pillbox, multidrug punch card, blister pouch, dose-dispensing serviceBackground
Adherence is defined as the extent to which a patient’s
behavior matches the agreed recommendations from the
prescriber [1]. Reported rates vary from 4.6% to 100% of
patients of all age classes with different medical condi-
tions and on long- or short-term treatments [1,2]. Mean
adherence rates for specific diseases are 88.3% for HIV
infection, 76.6% for cardiovascular disease, 67.5% for* Correspondence: fabienne.boeni@unibas.ch
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unless otherwise stated.diabetes mellitus and 58% for psychosis patients [2,3].
Adherence depends on patients’ capability (e.g., physical,
cognitive and economic) and willingness to initiate and
execute their treatment plan: if either is insufficient,
unintentional or intentional non-adherence will be the
consequence [4,5]. Non-adherence is known to impair
clinical, economic and humanistic outcomes [6-12]. In a
study across five European countries, increasing the per-
centage of patients adhering to antihypertensive treat-
ment to 70% was estimated to lead to a reduction of
cardiovascular related health-care costs by €332 million
($461 million) [13]. Reasons for non-adherence aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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needs and necessities have to be assessed to find the op-
timal aid for each patient.
Drug reminder packaging, such as weekly pillboxes or
multidrug punch cards, is widely used in everyday prac-
tice. It usually consists of a certain number of compart-
ments containing solid oral medication for specific
dosing times. Compared to other adherence-enhancing
programs, such as patient counseling, education or mo-
tivation [14], drug reminder packaging is a simple tech-
nical option and requires little resources on the patient’s
as well as on the provider’s side. The provision of drug
reminder packaging aims at enhancing adherence by
facilitating medication organization and intake, by de-
creasing medication errors and by (self-) monitoring
medication intake. Various authors suggest that drug re-
minder packaging supports mainly unintentionally non-
adherent patients, e.g., geriatric patients and patients
with complex drug regimens [4,15-17]. Previous reviews
with restrictive inclusion criteria investigated the effect
of reminder packaging on adherence and were inconclu-
sive [18-20]. This review uses evidence mapping [21,22]
to analyze data from a different perspective, highlighting
methodological strength and completeness of informa-
tion as well as research gaps, to identify areas for future
research.
Methods
A systematic review was conducted, complying with the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement. We proceeded by
following the evidence mapping methodology in four
steps: question development, question prioritization, evi-
dence search and selection, and data extraction [21].
Question development and prioritization
The study question was deduced from previous reviews.
An evidence report was composed after a preliminary
literature search. Keywords were defined based on the
results of this search. Experts were consulted to prioritize
the question.
Literature search
PubMed, Embase, CINAHL and PsycINFO were searched
for articles published up until September 2013. The key-
words used in the search strategy were the Medical Sub-
ject Headings (MeSH) term ‘medication adherence’ and 20
different terms for ‘drug reminder packaging’: unit dose*,
reminder pack*, unit of use pack*, pill organiser, pill or-
ganizer, medication packaging, medication container, pill
container, pill box, pillbox, pill calendar, calendar pack*,
calendar blister pack*, doset*, dosset*, blister pack*, pill
pack*, special packaging AND medication, drug pack*,
webster pack. The search was restricted to the English andGerman languages. Abstracts were screened and full text
articles of potential hits were retrieved. References of
retrieved articles were screened for relevant cross-
referenced articles.
Study selection and data extraction
The full text of potentially relevant articles was reviewed.
Inclusion criteria were any prospective controlled study
design, with at least one outcome being adherence, eco-
nomic, clinical or humanistic, with drug reminder pack-
aging as an intervention in any adherence-enhancing
program, for patients taking one or more oral medica-
tion (prescribed or over-the-counter) without the help of
a health-care professional. Trials were excluded if they
were performed in developing countries or if they used
drug reminder packaging with incorporated electronic
features (e.g., the Medical Event Monitoring System).
Drug reminder packaging included reusable multicom-
partment adherence aids (plastic pillboxes with several
compartments per day or per week filled by the patient
or pharmacy staff ), non-reusable multidrug punch cards
(frame cards with plastic cavities, sealed with a foil back-
ing, with typically 28 compartments, filled by pharmacy
staff, by a specialized company or an automated system)
and non-reusable unit-of-use packaging (e.g., blister
pouches attached to form flexible chains, with an unre-
stricted number of separated daily dosing times, filled by
automated systems) [23].
Data extracted included the author, publication year,
study design, duration of the intervention and follow-up,
description of the participants (e.g., age, clinical condi-
tions and number of medications), outcomes, method of
adherence measurement, type of drug reminder pack-
aging and additional interventions. The literature selection
and analysis of methodological issues were performed in-
dependently by two reviewers. Consensus regarding the
results was reached by discussion.
Methodological quality and completeness of information
The methodological quality of the studies was assessed
using the tool for quantitative studies developed for pub-
lic health topics by the Effective Public Health Practice
Project (EPHPP) group [24]. In brief, the tool is applic-
able to a variety of study designs other than randomized
controlled trials (RCTs), such as pre- and post-cohort
studies and case-control studies, and it has been vali-
dated [25]. It assesses eight components: (1) selection
bias, (2) study design, (3) confounders, (4) blinding, (5)
data collection method, (6) withdrawals and dropouts,
(7) intervention integrity and (8) analysis. Components 1
to 6 were rated as strong, moderate or weak. Based on
the rating of the components, studies were described as
of weak, moderate or strong methodological quality
[24,26]. The tool was adapted to the review question.
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it is not applicable in studies investigating adherence
with drug reminder packaging. The rating of criterion
‘(5) data collection method’ focused on adherence out-
comes [4]. Data collection was considered ‘valid and reli-
able’: (a) if the calculation of the medication possession
ratio, the calculation of the medication refill frequency,
therapeutic drug monitoring or a validated questionnaire
were applied as a single method; (b) if pill count or clin-
ical parameters were combined with at least one add-
itional adherence measurement method (e.g., therapeutic
drug monitoring) and (c) if appointment keeping was
combined with at least two additional adherence meas-
urement methods.
Following the recommendations of the CONSORT
(Consolidated Standards of Reporting Trials) statements
for non-pharmacological treatment [27] and the Cochrane
Handbook [28], eight additional criteria were selected to
assess completeness of information (Table 1). One point
was accredited per reported criterion. ‘Completeness of in-
formation’ was defined as the sum of the points divided by
eight, resulting in rates from 0 (no item on completeness
of information available) to 1 (all items on completeness
of information available). The packaging was defined as
‘described’ if the design (daily, weekly or monthly) and
the number of cavities were reported. Criteria 7 and 8,
concerning medication not packed in the drug reminder
packaging, were not applicable if it was stated that all
medication was packed into a drug reminder packaging
device. Results were calculated according to the adjusted
denominator.
Outcomes
Any measurement estimating taking adherence (i.e., an
indicator of taken medication) was extracted as an ad-
herence outcome. The Economic, Clinical and Humanistic
Outcomes (ECHO) model [29] was used to classify further
study outcomes. Therapeutic drug monitoring, biomarker
and physiological measurements were categorized asTable 1 List of additional criteria for completeness of
information
1 Description of drug reminder packaging
2 Description of medication packaging used by the control group
3 Description of intervention conditions
4 Description of control conditions
5 Description of all medication used in both groups
6 Specification of all medication packed in the drug reminder packaging
7 Specification of medication not packed in the drug reminder
packaging
8 Handling of medication not packed in the drug reminder packaging
Each criterion was accredited with 1 point; completeness of information was
calculated as the sum of the points divided by the number of
applicable criteria.clinical outcomes, unless they were part of a composite
adherence outcome. A listing of costs was considered
as an economic intermediary outcome if compared
between groups. Patient surveys on handling, opinion
or satisfaction with drug reminder packaging were
considered as humanistic intermediary outcomes if
comparison between groups was given.
Results
Of the total 855 identified references, 30 fulfilled the
inclusion criteria. The PRISMA flow diagram of study
inclusion and the PRISMA checklist are provided in
Additional files 1 and 2, respectively. According to the
EPHPP assessment tool for study design, 10 studies were
RCTs, 19 controlled clinical trials and 1 was a cohort
study (one group with a pre- and post-intervention com-
parison). Compared to the previously published reviews
[18-20], a total of 13 studies were additionally included,
from which 7 were controlled clinical trials, 5 RCTs and
1 was a cohort study.
Overall, the mean number of participants was 191
(range 14 to 2,081 participants). They were on average
62 years old (range 38 to 87 years, not described (n.d.)
in five studies), took an average of 3.9 medications
(range 1 to 9 medications, n.d. in 12 studies) and were
treated for hypertension (7), diabetes mellitus type 2 (3),
geriatric conditions (3), Helicobacter pylori infection (2),
HIV (2), vitamin supplementation (2), chronic mental
illness (2), hypercholesterolemia (1), epilepsy (1), pain
relief in cancer patients (1), anticoagulation (1), and
Chlamydia infection (1). Medical conditions were not
described in six studies of mainly elderly multimorbid
patients. The mean study duration was 5.4 months
(range 7 days to 14 months, n.d. in three studies). Table 2
is a summary of the studies.
Effect on adherence
Considerable variation exists between studies regarding
definitions, measures and calculations of adherence. Tak-
ing adherence was estimated in 27 studies (90%). Pill
count (15 studies) and patient self-report (12 of which 1
was electronic) were the most used measures. Other
methods included refill data (6), therapeutic drug moni-
toring (5), appointment keeping (2) and clinical mea-
sures (2). Eleven studies used composite adherence
measures. The calculation of adherence was unclear in
three studies [42,47,57].
A significant effect of drug reminder packaging was re-
ported in 17 studies and concerned at least one of the
measured adherence parameters. Six of these 17 studies
were not incorporated in the previous reviews (Table 2).
Twelve studies reported significant adherence improve-
ment in the group with drug reminder packaging as part of a
multiple intervention strategy [30,31,37,40,41,49,50,53-57].
Table 2 Summary of the 30 studies included
Number Lead
author






1 Ascione [30] CCT 158 n.d. Drug reminder packaging,
counseling
n.d. A: Self-report*: Unclear Strong 0.13
2 Azrin [31] CCT 39 2 m a. Drug reminder packaging,




A: Pill count*: a. vs baseline: 95.03 vs
76.24 (P < 0.05, Ø CI)
Strong 0.13
b. Drug reminder packaging,
counseling vs
b. vs baseline: 92.01 vs
69.52 (P < 0.01, Ø CI)








4 Binstock [33] CCT 112 12 m a. Counseling vs n.d. A: Self-report: a., b., c.: n.s. Weak 0.25
b. Drug reminder packaging,
counseling vs
C: sBP*, dBP*: b. vs a.: 133/80 mmHg vs
148/89 mmHg (P < 0.01,
Ø CI)
c. Drug reminder packaging,
counseling, other aids vs other
interventions
c. vs a.: 134/84 mmHg vs
148/89 mm Hg (P < 0.01,
Ø CI)
b. vs c.: n.s.
5 Crome
(1980) [34]
CCT 26 10 d Drug reminder packaging Multicompartment
adherence aid
A: Pill count: n.s. Weak 0.25
6 Crome
(1982) [35]
CCT 78 4 w Drug reminder packaging Multidrug punch card A: Pill count: n.s. Weak 0.25
7 Eshelman
[36]
CCT 100 n.d. Drug reminder packaging n.d. A: TDM*: ‘Adherent’ patients: 97%








A: Self-report*: Total Morisky score: 3.3 vs
2.9 (P = 0.006, Ø CI)
Moderate 0.13
Rate of patients with a
Morisky score of 0: 29% vs
49% (P = 0.04, Ø CI)
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9 Henry [38] CCT 119 10 d Drug reminder packaging,
counseling, other aids






RCT 184 2 m Drug reminder packaging Multicompartment
adherence aid





CCT 297 Unclear Drug reminder packaging







A: Pill count*: Patients who took >90%
of pills: 93% vs 87%
(P = 0.05, Ø CI)
Moderate 0.38
Self-report*: Positive answer to
question ‘forgot to take
pills’: 21 % vs 31 %
(P = 0.05, Ø CI); self-report
total score: n.s.
TDM: n.s.
12 Lee JK [40] RCT 200 14 m Drug reminder packaging,
counseling, regular follow-up
Multidrug punch card A: Pill count*: 95.5 vs 69.1 (P < 0.001,
Ø CI)
Strong 1.0
C: sBP*: Drug reminder packaging
vs baseline: −6.9 mmHg
(P = 0.005, CI −10.7- (−3.1)
mm Hg)
dBP*: Drug reminder packaging
vs baseline: −2.5 mm Hg
(P = 0.04, CI −4.9-(−0.2)
mm Hg)
LDL-C*: Drug reminder packaging
vs baseline at 8 m:
-4.8 mg/dl (P = 0.001,
CI −7.8-(−1.9) mg/l)
Drug reminder packaging
vs baseline at 14 m: n.s.




A: Pill count*: ITT1 (patients unavailable
for follow-up took 100%
[cg] or 0% [ig] of drugs):
Weak 0.25
No. of patients with >60%
of pills taken: n.s.
Patients with > 90% of
pills taken: 87% vs 71%
(P < 0.05, Ø CI)
ITT2 (patients unavailable
for follow-up took 0%
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Patients with >60% of
pills taken: 94% vs 78%
(P < 0.05, Ø CI)
Patients with > 90% of
pills taken: 87% vs 59%
(P < 0.01, Ø CI)
14 MacDonald
[42]




A: Unclear - Weak 0.25
15 Maier [43] RCT 2,081 6 m Drug reminder packaging Multicompartment
adherence aid
C: HbA1C*: -0.74% vs -0.53%




CCT 42 5 m Drug reminder packaging Multicompartment
adherence aid
A: MRC*: 75.8% vs 39.3% (Ø P, CI) Weak 0.13
Drug reminder packaging
vs baseline: 75.8% vs
46.8% (P < 0.01, Ø CI)
Appointment
keeping*:
76.1% vs 73.3% (Ø P, CI)
Drug reminder packaging
vs baseline: 76.1% vs












P < 0.05, Ø CI)
17 Miaskowski
[45]




C: Pain reduction*: Relieve in average, worst
and least pain: Ø numbers













given (P < 0.0001, Ø CI)
Taken: Ø numbers given
(P < 0.001, Ø CI)
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Self-report: No. of patients reporting
all medication taken: 9 vs










A: Pill count (+/− self-
report if pills were
not available):
n.s. Moderate 0.38
C: INR*: Sub-therapeutic INR
values (<2) vs baseline:
35% vs 60% (P = 0.04,
Ø CI)
Time spent in therapeutic
range vs baseline: 56% vs
32% (P = 0.03, Ø CI)











A: MRF*: ‘Adherent’ patients: 88%




baseline: 88% vs 48%




C: Seizure frequency*: Frequency of seizures vs
baseline: 2.5 vs 6 (P < 0.01,
Ø CI)




A: Pill count*: No. of patients who took
≥95% of pills: Drug
reminder packaging ±mi
> mi, Ø numbers given
(P < 0.01, Ø CI)
Weak 0.63
C: BP*: Drug reminder packaging
+mi vs baseline: Ø











on-time (± 5 d): 80.4% vs
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C: dBP*: No. of patients with
decreased dBP at 12 m:










RCT 68 8 m Drug reminder packaging (Multi-)drug punch
card
C: dBP*: -5.8 mmHg vs 0.1 mmHg
(P = 0.0041, Ø CI)
Moderate 0.13
sBP: n.s.
HbA1C*: -0.95% vs -0.15%
(P = 0.026, Ø CI)




CCT 258 12 m Drug reminder packaging ± rr,
factorial
Unit-of-use packaging A: MPR* Drug reminder packaging
vs cg: 0.71 vs 0.58 (P≤
0.05, Ø CI)
Weak 0.33
rr + drug reminder
packaging vs cg: 0.87 vs
0.58 (P ≤ 0.05, Ø CI)
rr + drug reminder
packaging vs drug
reminder packaging: 0.87
vs 0.71 (P ≤ 0.05, Ø CI)




+$74.09 (P ≤ 0.05, Ø CI)
All other expenditure: n.s.




+$124.86 (P≤ 0.05, Ø CI)
Physician
expenditure*:
−$66.79 (P ≤ 0.05, Ø CI)
Laboratory
expenditure*:
−$18.05 (P ≤ 0.05, Ø CI)
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CCT 304 12 m Drug reminder packaging ± rr,
factorial
Unit-of-use packaging A: MPR* Drug reminder packaging
vs cg: 0.67 vs 0.56
(P ≤ 0.05, Ø CI)
Weak 0.33
rr + drug reminder
packaging vs cg: 0.79 vs
0.56 (P ≤ 0.05, Ø CI)
rr + drug reminder
packaging vs drug
reminder packaging: 0.79
vs 0.67 (P ≤ 0.05, Ø CI)




+$48.17 (P ≤ 0.05, Ø CI)
All other expenditure: n.s.




+$104.39 (P≤ 0.05, Ø CI)
Physician
expenditure*:
−$78.41 (P ≤ 0.05, Ø CI)








CCT 372 7 d Drug reminder packaging ±
videotape ± telephone interview,
factorial
Unit-of-use packaging A: Self-report (non-
compliance score)*:
Drug reminder packaging
vs cg: 30.2 vs 50.7
Moderate 1.0
(P < 0.001, Ø CI)
Drug reminder packaging
+ videotape vs cg: 5.5 vs
11.1 (P < 0.001, Ø CI)
28 Valenstein
[56]
RCT 118 12 m Drug reminder packaging,
counseling, other aids
Multidrug punch card A: MPR*: At 6 m: 0.91 vs 0.64
(P < 0.0001, Ø CI)
Moderate 0.17
At 12 m: 0.86 vs 0.62


















Table 2 Summary of the 30 studies included (Continued)
CAM*: At 6 m: 26% vs 9%
(P = 0.0003, Ø CI)
(MPR + self-report +
TDM)
At 12 m: 17% vs 9%







29 Ware [57] CCT 84 3 m Drug reminder packaging,
counseling





At discharge: 86.7% vs
66.7% (P = 0.03, Ø CI)
At 10 d: 69% vs 41%
(P = 0.02, Ø CI)
At 1 m: 64.4% vs 38.5%
(P = 0.03, Ø CI)
At 2 m: 57.8% vs 28.2%
(P = 0.01, Ø CI)
At 3 m: 48.9% vs 23.1%
(P = 0.03, Ø CI)
30 Winland-
Brown [58]
CCT 61 6 m Drug reminder packaging Multicompartment
adherence aid
A: Pill count: n.s. Weak 0.13




Physician visits: Mean (per patient) vs
baseline: 1.5 vs 1.5
(Ø P, CI)
Hospital admission: No. of patients vs
baseline: 7 vs 4 (Ø P, CI)
Home visit: No. of patients vs
baseline: 0 vs 0 (Ø P, CI)
Transition to a higher
level of care:
Not reported
The 13 additional studies compared to previous reviews [18-20] are designated in bold. * indicates statistically significant outcomes.
13C-UBT, 13C-urea breath test; A, adherence outcome; (s, d)BP, (systolic, diastolic) blood pressure; C, clinical outcome; CAM, composite adherence measure; CCT, controlled clinical trial; cg, control group; CI,
confidence interval; d, days; E, economic outcomes; H, humanistic outcomes; HbA1C, glycated hemoglobin; ig, intervention group; INR, international normalized ratio; LDL-C, low-density lipoprotein
cholesterol; m, months; mi, multiple interventions; MRC, medication refill compliance; MRF, medication refill frequency; No., number; n.s., not significant; RCT, randomized controlled trial; rr, refill reminder;
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drug reminder packaging was a single intervention
[36,39,44,46,50,51,53-55]; however, it was less pronoun-
ced in direct comparison with multiple interventions
[50,53-55].
Methodological quality and completeness of information
Methodological quality was rated as strong for 5 studies,
moderate for 12 and weak for 13. Overall, weaknesses
were in the methods used for data collection (mostly not
valid and not reliable) and the report of confounders
and their comparison between groups (insufficient or
missing). The most accurate standard in statistical ana-
lysis, the intention-to-treat analysis, was applied by
seven studies. The number of studies with strong and
moderate methodological quality doubled after 1996, the
year of the first publication of the CONSORT statements
[59], while the number of weak methodological quality
studies diminished by a factor of 3.
Completeness of information ranged from 0 to 1.0
with a mean score of 0.3. Two studies [40,55] gave
complete information for all required details. Reported
criteria for the completeness of information are depicted
in Figure 1. Criteria 7 and 8 were not applicable for 5
studies [40,53-56] and practically non-existent in all 25
remaining studies (criterion 7: 0; criterion 8: 1). Informa-
tion on the person in charge and place of intervention
were often missing from the description of the interven-
tion and control conditions. Figure 2 shows the included
studies according to their methodological quality, com-
pleteness of information and outcome measures.
Outcomes
Two studies assessed direct costs as intermediary eco-
nomic outcomes [53,54] and there was a significant in-
crease in prescription costs. However, a cost-effectiveness0
1. Description of drug reminder packaging
2. Description of medication packaging of the control group
3. Description of intervention conditions
4. Description of control conditions
5. Desciption of all medication used in both groups
6. Specification of all medication packed in the drug reminder packaging
7. Specification of medication not packed in the drug reminder packaging
8. Handling of medication not packed in the drug reminder packaging
Figure 1 Distribution of the eight criteria defined for the completeneanalysis that would qualify as an economic outcome ac-
cording to the ECHO model was not reported.
Clinical outcomes were measured in 16 studies using
one or several parameters: blood pressure (6), glycated
hemoglobin (HbA1C) (2), psychiatric symptoms (2), low-
density lipoprotein cholesterol (LDL-C) levels (1), pain
reduction (1), number of seizures (1), plasma levels of
anticonvulsant drugs (1), viral load (1), CD4 cell count
(1), number of opportunistic infections (1), hospitaliza-
tions (1), percentages of sub-therapeutic international
normalized ratio (INR) values (1), time within the thera-
peutic INR range (1) and 13C-urea breath test (1).
Of these 16 studies, 7 were not incorporated in the pre-
vious reviews. Five of the seven additional studies showed
a statistically significant effect [40,43-45,47]. In one study,
LDL-C levels and blood pressure were significantly re-
duced after eight months compared to the baseline for pa-
tients using drug reminder packaging (LDL-C: −4.8 mg/dl,
P = 0.001; systolic blood pressure: −6.9 mmHg, P = 0.005;
diastolic blood pressure: −2.5 mmHg, P = 0.04) [40]. In a
study with diabetes mellitus type 2 patients, HbA1C was
significantly reduced (−0.74%, P < 0.0001) and patients
who took ≥5 tablets/day, ≥3 hypoglycemic drugs/day and
were <55 years old had the largest benefit from drug re-
minder packaging [43]. In other studies, pain reduction
was effective in cancer patients (P < 0.0001) [45], the
number of opportunistic infections and hospitalizations
decreased significantly in HIV patients (P < 0.05) [44], the
percentages of sub-therapeutic INR values with oral
anticoagulation (warfarin) decreased (P = 0.04) and time
within the therapeutic INR range increased significantly
(P = 0.03) [47]. Of the ten studies with multiple
adherence-enhancing strategies in the intervention group,
six showed significantly improved clinical outcomes
[33,40,45,47,49,50]. The clinical outcomes of all studies
are presented in Table 2.2 4 6 8 10 12 14 16 18 20
No. of studies reporting on criterion No. of studies not applicable to criterion
ss of information (n = 30 studies).
Figure 2 Consolidation of results of outcomes, methodological quality and completeness of information. Each box represents one
study numbered as in Table 2, plotted in a segment of reported outcome(s) and at a height based on its methodological quality. Completeness of
information is indicated by the size of the box, with values between 0 (e.g., study no. 21) and 1 (e.g., study no. 12). Bold frames are for the additionally
included studies compared to previously published reviews [18-20]. No filling indicates at least one outcome was statistically significant and shading
indicates none of the outcomes were statistically significant. A, adherence; C, clinical outcome; E, economic outcome; H, humanistic outcome.
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The usability of drug reminder packaging was rated sig-
nificantly higher than the usability of usual packaging
[52]. Safety issues related to the intervention were ad-
dressed by two studies [49,56].
Clear gaps emerged from the overall results. Aside from
methodological weaknesses (under-reporting of quality
issues) and incomplete information (under-reporting of
control settings and specification of medication), eco-
nomic outcomes (cost-effectiveness), humanistic out-
comes and safety issues are lacking.Discussion
Although more than half of the studies included in this
review reported significant effects, only three studies
were graded as methodologically strong. Drug reminder
packaging had a significant effect on adherence in a geri-
atric population [30], for chronic mental illness [31] and
for cardiovascular disease [40]. The overall effect of drug
reminder packaging on adherence parameters remains
inconclusive, as reported by previous reviews with more
restrictive selection criteria [18-20]. Three studies re-
ported a significant effect on adherence but not on clin-
ical outcomes [31,50,56]. Thus, the question of how
much adherence is necessary for altering treatment suc-
cess is raised and there is a requirement to present the
clinical benefits for the patients [60]. We observed that
drug reminder packaging offers a broad field of application
and is mostly used for polypharmacy. As a consequence,
disease-unspecific, generalizable clinical outcomes like
morbidity or re-hospitalization rates would provide viable
and comparable results rather than measures of disease-
specific clinical parameters. Only two trials investigated
such outcomes [44,58], with one showing that drugreminder packaging significantly reduced the mean
hospitalization rate.
We included five RCTs in the evidence map that were
excluded by three previous reviews [18-20] because of
their multiple intervention design. In a direct compari-
son (factorial trials), the effect was higher with multiple
interventions, which is consistent with previous findings
[14,18]. Yet, the evidence is limited, for these trials were
graded as weak in methodological quality.
The overall methodological quality of the studies in-
cluded is poor and thus evidence for the effect of drug
reminder packaging on adherence is low. We used a
quality assessment tool that is applicable to a variety of
study designs and was specifically developed to provide
research evidence for studies on public health services
with a focus on behavior change education [24]. In com-
parison to previous reviews, we were able to include
four additional studies of strong methodological quality
[30,38,40,43]. However, information on intervention
and control settings was incomplete in three of these
additional studies (completeness scores: 0.13, n = 2; 0.25,
n = 1). As a consequence, being graded as strong and
complying with all the criteria for completeness of infor-
mation was observed in one out of the 30 studies
included [40]. It therefore represents a thin basis for in-
formed clinical decision support.
The increasing number of methodologically strong tri-
als after 1996, the year when the CONSORT statements
were released, is intriguing and probably follows from
under-reporting in studies published before 1996. Vari-
ous authors indeed stated that complete reporting of
methodological quality according to the CONSORT cri-
teria was inadequate, but that poor reporting did not
necessarily correlate with the quality of how the trial
was conducted [61-64]. The CONSORT statements of
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of both, the experimental treatment and the comparator’
[27] and omission of trial details has been shown to lead
to decreased uptake of trial results into clinical practice
[65,66]. Thus, to obtain valuable and reliable study re-
sults, high methodological quality and detailed informa-
tion are crucial.
Most studies were designed as RCTs, which provide
the most reliable results through the minimization of
confounding. However, RCTs might not be the appropri-
ate design for all research questions and settings, espe-
cially in the field of behavior research. Alternative
designs might be worth considering. Firstly, randomized
allocation of study participants to a predefined interven-
tion may not be practicable since tailored interventions,
in respect of patients’ needs and abilities, are expected
to be the most effective [14]. Secondly, in studies on
survival outcomes for HIV patients, investigating adher-
ence-enhancing strategies in a randomized controlled
fashion has been declared to be ethically difficult [67,68].
The reason for this declaration was the assumption that
allocation to the control condition equaled withholding
a tool, which could possibly lead to higher survival rates
through an optimal clinical response due to increased
adherence [67,68]. Thirdly, behavioral interventions are
often complex and can only be controlled poorly under
real-life conditions and therefore randomization might not
be practical in a primary care setting [69]. Consequently,
confounding could even persist despite randomization.
Alternatives to conventional randomization designs, i.e.,
randomization at the patient level, include pre- and post-
cohort studies, historical control studies, pre-randomized
designs and cluster randomization [70].
More studies could be included and research gaps iden-
tified using our approach of evidence mapping. Patient-
relevant disease-unspecific long-term clinical outcomes,
e.g., (re-)hospitalization, admission to a nursing home,
etc., were neglected. Economic outcomes as defined by
Kozma et al. [29] were not reported in any study on
drug reminder packaging. This may be due to the fact
that drug reminder packaging is generally supposed to
be inexpensive, and thus cost-effective. Humanistic
outcomes were measured in two studies [52,56], which
is insufficient for judging whether a condition opti-
mally treated through drug reminder packaging leads
to increased quality of life. Improved adherence could
lead to increased adverse events as well. However, safety
issues were reported by two studies only [49,56]. Patient
satisfaction and other aspects of safety, such as opening
medication packaging, confusion with new packaging and
decreased ability to identify one’s own medication [71-74],
were hardly mentioned by the studies.
Our study has strengths. First, evidence mapping allows
the inclusion of more studies and gives an overall view ofthe subject. Second, the tool used to assess methodological
quality is independent of study design (EPHPP) and was
developed specifically to assess studies within the scope of
public health. Third, with completeness of information,
a further element for judging quality is added. Fourth,
the consolidation of adherence outcomes and economic,
clinical and humanistic parameters allows an overall pres-
entation and highlights research gaps. Our study has limi-
tations also, such as the language restriction, which led to
the exclusion of articles considered relevant. Information
may also have been missed due to the exclusion of studies
performed in developing countries.
A suggestion for future research is to develop meth-
odologically strong studies reporting complete informa-
tion to clarify the effect of drug reminder packaging on
medication adherence.Conclusions
New information was extracted from the 30 studies in-
cluded and several studies had statistically significant
and relevant results for adherence and clinical outcomes
with drug reminder packaging. However, firm conclu-
sions cannot be given for the effect of drug reminder
packaging on adherence, mainly because the studies lack
methodological quality and the information was incom-
plete. The main research gaps concerned economic,
disease-unspecific clinical outcomes and humanistic out-
comes. Safety issues and satisfaction with the interven-
tion were marginally reported. Researchers of behavioral
interventions might consider alternative study designs
for similar research questions, without neglecting meth-
odological issues and reporting important details. Future
research should aim at filling the observed gaps with a
focus on patient safety and the benefit to patients as well
as on implementable and valuable interventions. Drug
reminder packaging should be distributed with respect
to patient needs, requests and abilities.Additional files
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